Drug Profile
Research programme: antibacterials - Sun Pharmaceutical Industries
Alternative Names: RBx 1000075; RBx 1000276; RBx 6247; RBx 8700Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Class Oxazolidinones
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-positive infections; Respiratory tract infections; Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-infections in India
- 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy